The specimens collected will be used to evaluate matrix equivalency in an immunoassay in development for the detection of IgG or IgA or IgM antibodies to SARS - CoV2 in human serum. These reagents are for in vitro diagnostic use only.
The objective of this study is to acquire paired serum, plasma and whole blood collected on a
collection card from subjects with no known history of COVID-19 infection. The specimens will
be collected at Biomerica in Irvine CA for specimen collection, banking, and matrix
equivalency studies for projects in development at Biomerica for detection to IgG or IgA or
IgM antibodies to Sars-CoV2 antibodies. Subject will also be asked to self-collect a nasal
swab for COVID-19 PCR
Inclusion Criteria:
- Aged 21 and older
- Able to read, speak, and understand English
- Must weigh a minimum of 110 pounds
- Willing and able to donate 20 mLs of whole blood via venipuncture. [approximately ˂ 2
tablespoons]
- Willing and able to donate 0.040 mLs of whole blood via fingerstick
- Willing and able to sign the informed consent (self or authorized representative)
- Willing and able to self-collect a nasal swab per the provided instruction shee
Exclusion Criteria:
- Aged less than 21 years old
- Unable to provide consent.
- Unable to donate blood via venipuncture and fingerstick.
- Unable to self-collect a nasal swab
Biomerica, Inc.
Irvine, California, United States
Elisabeth Laderman, Ph.D., Principal Investigator
Biomerica, Inc.